Targeting both wild-type and mutant KRAS in cancer has been notably unsuccessful; in particular, several high-throughput screens of KRAS-mutant cancer cell lines identified compounds which subsequently only partially reduced tumor volumes in xenograft models55,56. The gene discussed is KRAS; the disease is neoplasm.